Faculty

Institution

Unit

Venue

Bernard Weissman

Professor

University of North Carolina at Chapel Hill

Affiliations

School of Medicine

Pathology and Laboratory Medicine

Bernard Weissman is currently serving as a Pathology And Laboratory Medicine Professor at University of North Carolina At Chapel Hill.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Bernard Weissman

University of North Carolina at Chapel Hill

Professor

You can click a keyword to filter the displayed items

cancer biology tumor biology oncology cancer research genetics cancer genetics cell biology molecular biology medicinal research oncogenes cancer genomics molecular cancer cancer treatment gene expression cancer care dermatology tumor suppressors cancer cells cellular therapy carcinogenesis gynecologic oncology leukemia tumor targeting genome biology genomics cancer growth cancer management hypercalcemic type cytogenetics chromatin remodeling molecular cell biology mammalian biology chromosome biology small cell carcinoma protein science cellular physiology thoracic oncology metastasis molecular and cellular biology cancer imaging cell regulation cellular biology anti-cancer agents cell physiology molecular regulation cell research skin cancer liver cancer gene function cutaneous biology cancer risk cell cycle gene regulation malignant rhabdoid tumors melanoma viral oncology tumor heterogeneity medical genetics protein expression hematological malignancies epigenetic changes human cell hybrids growth factors tumor suppressor genes clinical medicine cell culture tumorigenic expression dual loss increased expression tumor assay tumorigenic phenotype tumor formation tumor cell line primary lung cancers poor prognosis growth factor beta tumoral pathology radiation oncology malignant disease histopathology lung cancer pathology oxidative stress

Notable Scholarly Works

Notable Federal Grants

Collaborators

Arid1A Loss is Associated With Increased Nrf2 Signaling in Human Head and Neck Squamous Cell Carcinomas. PLoS ONE (2024)

Vinh NguyenTravis P. SchrankMichael B. MajorBernard E. Weissman

pathologycancer biologycancer researchoncologyredox signalingoral cancerradiation oncologyneck oncologytumor biologycarcinogenesiscell biologyskin cancerplo biology

Figure S4 From Nrf2 Activation in Trp53;P16-Deficient Mice Drives Oral Squamous Cell Carcinoma. (2024)

Samera H. HamadRani S. SellersNathan WamsleyPaul ZolkindTravis P. SchrankMichael B. MajorBernard E. Weissman

pharmacologycancer immunotherapymolecular cancercancer biologytumor suppressorsgene therapyoncogenescancer researchoncologycancer genomicsoral cancerleukemiacellular therapytumor biologycancer geneticsdermatologymedicinal researchcell biology

Mutant Nrf2E79Q Enhances the Promotion and Progression of a Subset of Oncogenic Ras Keratinocytes and Skin Tumors. Redox Biology (2024)

John G. WitherspoonJonathan R. HallDereje JimaHannah M. AtkinsNathan T. WamsleyMichael B. MajorBernard E. WeissmanRobert C. Smart

oncogenic agentoncogenesoncologyskin tumorsredox biologyoncogenic ras keratinocytesdermatology

Nrf2 Activation in Trp53;P16 Deficient Mice Drives Oral Squamous Cell Carcinoma. Cancer research communications (2024)

Samera H. HamadRani S. SellersNathan WamsleyPaul ZolkindTravis P. SchrankMichael B. MajorBernard E. Weissman

pharmacologycancer immunotherapycancer biologycancer treatmentmedicinetumor targetingoncogenescancer researchoncologycancer genomicsleukemiacellular therapytumor biologycancer geneticsmedicinal researchcell biologycancer caretherapeutic targets

Racial Differences in Endometrial Cancer Genomics and Outcomes Using Uncseqtm Targeted Dna Sequencing. (2024)

Meredith NewtonJason D. MerkerWeida GongSushant PatilXianming TanDavid L. CocoranAdam PfefferleMichele C. HaywardRussell BroaddusHazel B. NicholsAndrew F. OlshanBernard E. WeissmanTemitope O. KekuVictoria L. Bae-Jump

geneticsoutcomes researchbioinformaticsgenomicsdna sequencingraceracial differencesgynecologic oncologyafrican american studiesracial discriminationendometrial cancer genomics

Yap1 Status Defines Two Intrinsic Subtypes of Lcnec With Distinct Molecular Features and Therapeutic Vulnerabilities. Clinical Cancer Research (2024)

C. Allison StewartLixia DiaoYuanxin XiRunsheng WangKavya RamkumarAlejandra G. SerranoAzusa TanimotoB. Leticia RodriguezBenjamin B. MorrisLi ShenBingnan ZhangYan YangSamera H. HamadRobert J. CardnellAlberto DuarteMoushumi SahuVeronica Y. NovegilBernard E. WeissmanMichael FrumovitzNeda KalhorLuisa Solis SotoPedro da RochaNatalie VokesDon L. GibbonsJing WangJohn V. HeymachBonnie GlissonLauren Averett ByersCarl M. Gay

pharmacologypathologycancer immunotherapymolecular cancerbreast cancermorphological evidenceoncogenesoncologycancer genomicsmolecular biologytumor biologytherapeutic vulnerabilitiesmedicinal researchmammalian biologyprotein sciencetherapeutic targetsintrinsic subtypes

Abstract Po-053: Chemical Suppression of Dhfr Induces Nrf2 Inhibition and Tumor Regression. Clinical Cancer Research (2023)

Paul ZolkindHarit PandaCaroline KrallBrittany BowmanNathan WamsleyBernard WeissmanBen Major

pathologytumor regressionanti-cancer agentsclinical researchcancer biologymolecular cancercancer researchfunctional modificationtumor biologypharmacologycancer treatmentgene expressiononcologychemical suppressioncancer carecancer managementradiation oncologyleukemiamedicinal research

Alanine Supplementation Exploits Glutamine Dependency Induced by Smarca4/2-Loss. Nature Communications (2023)

Xianbing ZhuZheng FuShary Y. ChenDionzie OngGiulio AcetoRebecca HoJutta SteinbergerAnie MonastVirginie PilonEunice LiMonica TaKyle ChingBianca N. AdamsGian L. NegriLuc ChoiniereLili FuKitty PavlakisPatrick PirrotteDaina Z. AvizonisJeffrey TrentBernard E. WeissmanRamon I. Klein GeltinkGregg B. MorinMorag ParkDavid G. HuntsmanWilliam D. FoulkesYemin WangSidong Huang

pharmacologymedicinal chemistrydrug discoveryimmunologycell biologydrug metabolism

Data From Gene Silencing Associated With Swi/Snf Complex Loss During Nsclc Development. (2023)

Shujie SongVonn WalterMehmet KaracaYing LiChristopher S. BartlettDominic J. SmiragliaDaniel SerberChristopher D. SproulChristoph PlassJiren ZhangD. Neil HayesYanfang ZhengBernard E. Weissman

geneticsmolecular biologycell and molecular biologynsclc development

Data From Histone Deacetylase Inhibitors Synergize With Catalytic Inhibitors of Ezh2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. (2023)

Yemin WangShary Yuting ChenShane ColborneGalen LambertChae Young ShinNancy Dos SantosKrystal A. OrlandoJessica D. LangWilliam P.D. HendricksMarcel B. BallyAnthony N. KarnezisRalf HassT. Michael UnderhillGregg B. MorinJeffrey M. TrentBernard E. WeissmanDavid G. Huntsman

pathologytumor targetinghistone deacetylase inhibitorsovarian canceranti-cancer agentsgynecologycancer biologymolecular cancercancer researchcancer genomicstumor biologypharmacologyoncologysmall cell carcinomacellular therapyenzymescancer managementcancer imagingantitumor activitycatalytic inhibitorsenzyme inhibitionmedicinal researchhypercalcemic type

1
2
3
4
5
16
10 / page

Bernard Weissman

Professor

University of North Carolina at Chapel Hill

Affiliations

School of Medicine

Pathology and Laboratory Medicine

Bernard Weissman is currently serving as a Pathology And Laboratory Medicine Professor at University of North Carolina At Chapel Hill.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Bernard Weissman

University of North Carolina at Chapel Hill

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Arid1A Loss is Associated With Increased Nrf2 Signaling in Human Head and Neck Squamous Cell Carcinomas. PLoS ONE (2024)

Vinh NguyenTravis P. SchrankMichael B. MajorBernard E. Weissman

pathologycancer biologycancer researchoncologyredox signalingoral cancerradiation oncologyneck oncologytumor biologycarcinogenesiscell biologyskin cancerplo biology

Figure S4 From Nrf2 Activation in Trp53;P16-Deficient Mice Drives Oral Squamous Cell Carcinoma. (2024)

Samera H. HamadRani S. SellersNathan WamsleyPaul ZolkindTravis P. SchrankMichael B. MajorBernard E. Weissman

Mutant Nrf2E79Q Enhances the Promotion and Progression of a Subset of Oncogenic Ras Keratinocytes and Skin Tumors. Redox Biology (2024)

John G. WitherspoonJonathan R. HallDereje JimaHannah M. AtkinsNathan T. WamsleyMichael B. MajorBernard E. WeissmanRobert C. Smart

oncogenic agentoncogenesoncologyskin tumorsredox biologyoncogenic ras keratinocytesdermatology

Nrf2 Activation in Trp53;P16 Deficient Mice Drives Oral Squamous Cell Carcinoma. Cancer research communications (2024)

Samera H. HamadRani S. SellersNathan WamsleyPaul ZolkindTravis P. SchrankMichael B. MajorBernard E. Weissman

Racial Differences in Endometrial Cancer Genomics and Outcomes Using Uncseqtm Targeted Dna Sequencing. (2024)

geneticsoutcomes researchbioinformaticsgenomicsdna sequencingraceracial differencesgynecologic oncologyafrican american studiesracial discriminationendometrial cancer genomics

Yap1 Status Defines Two Intrinsic Subtypes of Lcnec With Distinct Molecular Features and Therapeutic Vulnerabilities. Clinical Cancer Research (2024)

Abstract Po-053: Chemical Suppression of Dhfr Induces Nrf2 Inhibition and Tumor Regression. Clinical Cancer Research (2023)

Paul ZolkindHarit PandaCaroline KrallBrittany BowmanNathan WamsleyBernard WeissmanBen Major

Alanine Supplementation Exploits Glutamine Dependency Induced by Smarca4/2-Loss. Nature Communications (2023)

pharmacologymedicinal chemistrydrug discoveryimmunologycell biologydrug metabolism

Data From Gene Silencing Associated With Swi/Snf Complex Loss During Nsclc Development. (2023)

Shujie SongVonn WalterMehmet KaracaYing LiChristopher S. BartlettDominic J. SmiragliaDaniel SerberChristopher D. SproulChristoph PlassJiren ZhangD. Neil HayesYanfang ZhengBernard E. Weissman

geneticsmolecular biologycell and molecular biologynsclc development

Data From Histone Deacetylase Inhibitors Synergize With Catalytic Inhibitors of Ezh2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. (2023)

1
2
3
4
5
16
10 / page

Similar Faculty Members

Eric J. Stanbridge

Institution

University of California, Irvine

genetics

cancer biology

Wael El-Rifai

Institution

University of Miami

molecular cancer

cancer biology

Erica Golemis

Institution

Temple University

oncology

cancer research

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Aristotelis Tsirigos

Institution

New York University

hi-c data analysis

health informatics

Charles Eberhart

Institution

Johns Hopkins University

oncology

neurology

Michele Pagano, MD

Institution

New York University

cell cycle

cell cycle control

Jonathan D Licht

Institution

University of Florida

oncology

pathology

John Digiovanni

Institution

University of Texas at Austin

cancer letter

molecular cancer

Harold L. Moses

Institution

Vanderbilt University

oncogene

molecular cancer

Similar Faculty Members

Eric J. Stanbridge

Institution

University of California, Irvine

genetics

cancer biology

Wael El-Rifai

Institution

University of Miami

molecular cancer

cancer biology

Erica Golemis

Institution

Temple University

oncology

cancer research

Devanand Sarkar

Institution

Virginia Commonwealth University

oncology

cancer research

Aristotelis Tsirigos

Institution

New York University

hi-c data analysis

health informatics

Charles Eberhart

Institution

Johns Hopkins University

oncology

neurology

Michele Pagano, MD

Institution

New York University

cell cycle

cell cycle control

Jonathan D Licht

Institution

University of Florida

oncology

pathology

John Digiovanni

Institution

University of Texas at Austin

cancer letter

molecular cancer

Harold L. Moses

Institution

Vanderbilt University

oncogene

molecular cancer